Related Experiment Video
Updated: Jun 12, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Natalizumab efficacy on cognitive impairment in MS
F Mattioli1, C Stampatori, F Bellomi
1Neuropsychology Unit, Spedali Civili of Brescia, Via Nikolajewka, 13, 25123, Brescia, Italy. flaviacaterina.mattioli@gmail.com
Summary
Natalizumab therapy significantly reduced relapse rates and improved cognitive functions, including memory and executive functions, in multiple sclerosis patients over two years.
Area of Science:
- Neuroscience
- Immunology
- Neurology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Neuropsychological impairment is a common and debilitating symptom in MS patients.
- Current therapies aim to reduce disease activity and manage symptoms.
Purpose of the Study:
- To evaluate the long-term efficacy of natalizumab therapy on neuropsychological impairment in Italian MS patients.
- To assess the impact of natalizumab on relapse rates and cognitive functions over one and two years.
Main Methods:
- Follow-up study on a cohort of 39 MS patients at 1 year and 11 patients at 2 years.
- Neuropsychological tests were administered to assess cognitive functions.
- Relapse rates were monitored.
Main Results:
- Significant reduction in MS relapse rates observed at 1 year.
- Marked improvement in the number of impaired neuropsychological tests and executive function/reasoning scores at 1 year.
- Cognitive improvements persisted at 2 years, with additional gains in memory and processing speed.
Conclusions:
- Natalalizumab therapy demonstrates sustained efficacy in managing MS.
- The treatment effectively addresses cognitive deterioration across multiple domains in MS patients.
- These findings support natalizumab as a valuable therapeutic option for comprehensive MS management.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:30Negative and Cognitive Symptoms of Schizophrenia
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...